Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Schizophrenia: overview and treatment options.

Literature DB >> 25210417

Schizophrenia: overview and treatment options.

Krishna R Patel, Jessica Cherian, Kunj Gohil, Dylan Atkinson.

Abstract

Schizophrenia is a complex disorder characterized by an array of symptoms. This heterogeneity has resulted in a lack of consensus regarding diagnostic criteria, etiology, and pathophysiology, and has complicated efforts to devise effective treatments.

Entities: Disease

Year: 2014 PMID： 25210417 PMCID： PMC4159061

Source DB: PubMed Journal: P T ISSN： 1052-1372

47 in total

Review 1. Practice guideline for the treatment of patients with schizophrenia, second edition.

Authors: Anthony F Lehman; Jeffrey A Lieberman; Lisa B Dixon; Thomas H McGlashan; Alexander L Miller; Diana O Perkins; Julie Kreyenbuhl
Journal: Am J Psychiatry Date: 2004-02 Impact factor: 18.112

2. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response.

Authors: Jean-Pierre Lindenmayer; Hong Liu-Seifert; Pandurang M Kulkarni; Bruce J Kinon; Virginia Stauffer; Sara E Edwards; Lei Chen; David H Adams; Haya Ascher-Svanum; Peter F Buckley; Leslie Citrome; Jan Volavka
Journal: J Clin Psychiatry Date: 2009-06-02 Impact factor: 4.384

Review 3. “Meta-guidelines” for the management of patients with schizophrenia.

Authors: Stephen M Stahl; Debbi A Morrissette; Leslie Citrome; Stephen R Saklad; Michael A Cummings; Jonathan M Meyer; Jennifer A O'Day; Laura J Dardashti; Katherine D Warburton
Journal: CNS Spectr Date: 2013-06 Impact factor: 3.790

4. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms.

Authors: A L Miller; J A Chiles; J K Chiles; M L Crismon; A J Rush; S P Shon
Journal: J Clin Psychiatry Date: 1999-10 Impact factor: 4.384

5. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors: J Kane; G Honigfeld; J Singer; H Meltzer
Journal: Arch Gen Psychiatry Date: 1988-09

6. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach.

Authors: Eric Q Wu; Lizheng Shi; Howard Birnbaum; Teresa Hudson; Ronald Kessler
Journal: Psychol Med Date: 2006-08-15 Impact factor: 7.723

7. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.

Authors: S Kapur; R B Zipursky; G Remington
Journal: Am J Psychiatry Date: 1999-02 Impact factor: 18.112

8. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.

Authors: Christoph U Correll; Peter Manu; Vladimir Olshanskiy; Barbara Napolitano; John M Kane; Anil K Malhotra
Journal: JAMA Date: 2009-10-28 Impact factor: 56.272

Review 9. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.

Authors: Anthony DeLeon; Nick C Patel; M Lynn Crismon
Journal: Clin Ther Date: 2004-05 Impact factor: 3.393

10. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

Authors: Troy A Moore; Robert W Buchanan; Peter F Buckley; John A Chiles; Robert R Conley; M Lynn Crismon; Susan M Essock; Molly Finnerty; Stephen R Marder; Del D Miller; Joseph P McEvoy; Delbert G Robinson; Nina R Schooler; Steven P Shon; T Scott Stroup; Alexander L Miller
Journal: J Clin Psychiatry Date: 2007-11 Impact factor: 4.384

86 in total

1. Comparative effects of sertraline, haloperidol or olanzapine treatments on ketamine-induced changes in mouse behaviours.

Authors: O J Onaolapo; T B Paul; A Y Onaolapo
Journal: Metab Brain Dis Date: 2017-05-15 Impact factor: 3.584

Review 2. Brexpiprazole: A Review in Schizophrenia.

Authors: James E Frampton
Journal: Drugs Date: 2019-02 Impact factor: 9.546

Review 3. Aripiprazole Lauroxil: A Review in Schizophrenia.

Authors: James E Frampton
Journal: Drugs Date: 2017-12 Impact factor: 9.546

4. Acute stress modifies oscillatory indices of affective processing: Insight on the pathophysiology of schizophrenia spectrum disorders.

Authors: Elizabeth Andersen; Alana Campbell; Susan Girdler; Kelly Duffy; Aysenil Belger
Journal: Clin Neurophysiol Date: 2018-12-04 Impact factor: 3.708

5. A QSAR model of Olanzapine derivatives as potential inhibitors for 5-HT2A Receptor.

Authors: Pooja Mitra; Aishwarya Rastogi; Mayank Rajpoot; Ajay Kumar; Vivek Srivastava
Journal: Bioinformation Date: 2017-10-31

6. A Phase 1, Open-Label, Single Dose Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant.

Authors: Ryan Dammerman; Sonnie Kim; Mathews Adera; Alex Schwarz
Journal: Psychopharmacol Bull Date: 2017-09-15

7. Ventilation and neurochemical changes during µ-opioid receptor activation or blockade of excitatory receptors in the hypoglossal motor nucleus of goats.

Authors: Thomas M Langer; Suzanne E Neumueller; Emma Crumley; Nicholas J Burgraff; Sawan Talwar; Matthew R Hodges; Lawrence Pan; Hubert V Forster
Journal: J Appl Physiol (1985) Date: 2017-08-24

8. Aberrant parasympathetic reactivity to acute psychosocial stress in male patients with schizophrenia spectrum disorders.

Authors: Elizabeth H Andersen; Gregory F Lewis; Aysenil Belger
Journal: Psychiatry Res Date: 2018-04-06 Impact factor: 3.222

Review 9. Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12.

Authors: Paula Morales; Israa Isawi; Patricia H Reggio
Journal: Drug Metab Rev Date: 2018-02-01 Impact factor: 4.518

10. Association between cortical volume and gray-white matter contrast with second generation antipsychotic medication exposure in first episode male schizophrenia patients.

Authors: Won Jong Chwa; Todd A Tishler; Catalina Raymond; Cathy Tran; Faizan Anwar; J Pablo Villablanca; Joseph Ventura; Kenneth L Subotnik; Keith H Nuechterlein; Benjamin M Ellingson
Journal: Schizophr Res Date: 2020-05-31 Impact factor: 4.939